MDHHS – MCIR Release Notes

Version 2023 – MCIR OLTP 2023 9.10.1 – RFC 227048 Release Date: November 1, 2023

Forecasting & Assessment – 1 Item

1. Remove "consider' recommendation for RSV MAB 200mg for 8 through 19 months (Ref # 2648)

Record with “consider” status per original CDC guidelines

Table

Description automatically generated with medium confidence

Record with “consider” removed per ***updated*** CDC guidelines

Table

Description automatically generated with low confidence

CDC Health Alert Network Advisory issues October 23, 2023

See the attached link for detailed information:

[Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season](https://emergency.cdc.gov/han/2023/han00499.asp)

**NOTE:** For those in the 8-19 Months age range, **who have received a dose**; This dose will appear under “Other Administrations” and not assessed or evaluated during this time.

If you have questions or need assistance, please contact your Field Representative or

**MCIR SOM Help Desk at** [MDHHS-MCIRHelp@michigan.gov](mailto:MDHHS-MCIRHelp@michigan.gov)